Diagnosis of a neurological disease

Patent metadata

Field	Value
Publication number	US-2015355177-A1
Application number	US-201514729609-A
Country	US
Kind code	A1
Filing date	Jun 3, 2015
Priority date	Jun 6, 2014
Publication date	Dec 10, 2015
Grant date	—

Abstract

The present invention relates to a method for diagnosing a disease, comprising the step detecting in a sample an autoantibody binding to the alpha 3 subunit of the human neuronal Na(+)/K(+) ATPase, an isolated and/or recombinant polypeptide comprising the alpha 3 subunit of the human neuronal Na(+)/K(+) ATPase, a use of a membrane-associated human Na(+)/K(+) ATPase or a variant thereof for the diagnosis of a disease, an isolated and/or recombinant polypeptide comprising the alpha 3 subunit of the human neuronal Na(+)/K(+) ATPase or a variant thereof, for use in the treatment of a disease, an autoantibody binding to said polypeptide and a method for isolating such autoantibody, a pharmaceutical composition, medical or diagnostic device or test kit comprising the polypeptide.

First claim

1 . A method for diagnosing a disease, comprising the step detecting in a sample an autoantibody binding to the alpha 3 subunit of the human neuronal Na(+)/K(+) ATPase.

2 . The method according to claim 1 , wherein the sample is a bodily fluid comprising antibodies.

3 . The method according to claim 1 , wherein the bodily fluid is selected from the group consisting of whole blood, serum, cerebrospinal fluid, and saliva.

4 . The method according to claim 1 , wherein the sample is from a patient suffering from or suspected to suffer from cancer.

5 . The method according to claim 4 , wherein the cancer is adenocarcinoma.

6 . The method according to claim 1 , wherein the sample is from a patient suffering from or suspected to suffer from a neurological disorder.

7 . The method according to claim 6 , wherein the neurological disorder is characterized by two or more symptoms selected from the group consisting of mixed movement disorder, acute decline of visual performance, dysarthria and dysphagia.

8 . An isolated and/or recombinant polypeptide comprising the alpha 3 subunit of the human neuronal Na(+)/K(+) ATPase or a variant thereof.

9 . The polypeptide according to claim 8 , wherein the polypeptide is immobilized.

10 . The polypeptide according to claim 8 obtained from a cell comprising a nucleic acid encoding said polypeptide or a tissue comprising said polypeptide.

11 . An isolated autoantibody capable of binding to an isolated and/or recombinant polypeptide comprising the alpha 3 subunit of the human neuronal Na(+)/K(+) ATPase or a variant thereof.

12 . The isolated autoantibody of claim 11 , wherein the autoantibody is in complex with the isolated and/or recombinant polypeptide.

13 . The isolated autoantibody of claim 11 , wherein the autoantibody is capable of binding to the alpha 3 subunit of the human neuronal Na(+)/K(+) ATPase.

14 . A method for isolating an autoantibody capable of binding to the polypeptide according to claim 8 , comprising the steps:
contacting a sample comprising the autoantibody with the polypeptide according to claim 8 under conditions compatible with formation of a complex, wherein said autoantibody binds to said polypeptide, isolating the complex formed in step a), dissociating the complex isolated in step b), and separating the autoantibody from the polypeptide.

15 . The method according to claim 14 , wherein the sample is from a patient suffering from or suspected to suffer from cancer.

16 . The method according to claim 15 , wherein the cancer is adenocarcinoma.

17 . The method according to claim 14 , wherein the sample is from a patient suffering from or suspected to suffer from a neurological disorder.

18 . The method according to claim 17 , wherein the neurological disorder is characterized by two or more symptoms selected from the group consisting of mixed movement disorder, acute decline of visual performance, dysarthria and dysphagia.

19 . A medical or diagnostic device comprising the polypeptide according to claim 8 .

20 . A test kit for the diagnosis of a disease, comprising the polypeptide according to claim 8 .

21 . The test kit according to claim 20 , further comprising a means for detecting a complex comprising the polypeptide and an autoantibody capable of binding to the polypeptide.

Assignees

• Euroimmun Medizinische Labordiagnostika Ag

Inventors

• Komorowski Lars
• Scharf Madeleine
• Miske Ramona
• Denno Yvonne
• Dettmann Inga-Madeleine
• Probst Christian
• Heidenreich Fedor
• Giess Ralf

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P25/14

  for treating abnormal movements, e.g. chorea, dyskinesia · CPC title

• C07K16/06

  from serum · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K16/40

  against enzymes · CPC title